Cargando…

A novel truncating variant in the LAMP2 gene in a young woman with hypertrophic cardiomyopathy and variable clinical course in the family

Detalles Bibliográficos
Autores principales:	Michalak, Ewa, Franaszczyk, Maria, Sobieszczanska-Malek, Malgorzata, Karcz, Maciej, Szymanska, Sylwia, Szczygiel, Justyna, Lutynska, Anna, Ploski, Rafal, Bilinska, Zofia T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667409/ https://www.ncbi.nlm.nih.gov/pubmed/33224350 http://dx.doi.org/10.5114/aoms.2019.88610

Ejemplares similares

Titin Truncating Variants in Dilated Cardiomyopathy – Prevalence and Genotype-Phenotype Correlations
por: Franaszczyk, Maria, et al.
Publicado: (2017)

Severe Course of Peripartum Cardiomyopathy and Subsequent Recovery in a Patient with a Novel TTN Gene-Truncating Mutation
por: Kryczka, Karolina E., et al.
Publicado: (2018)

The BAG3 gene variants in Polish patients with dilated cardiomyopathy: four novel mutations and a genotype-phenotype correlation
por: Franaszczyk, Maria, et al.
Publicado: (2014)

Titin-Related Dilated Cardiomyopathy: The Clinical Trajectory and the Role of Circulating Biomarkers in the Clinical Assessment
por: Chmielewski, Przemysław, et al.
Publicado: (2021)

A Novel DSP Truncating Variant in a Family with Episodic Myocardial Injury in the Course of Arrhythmogenic Cardiomyopathy—A Possible Role of a Low Penetrance NLRP3 Variant
por: Chmielewski, Przemysław, et al.
Publicado: (2020)

A study in Polish patients with cardiomyopathy emphasizes pathogenicity of phospholamban (PLN) mutations at amino acid position 9 and low penetrance of heterozygous null PLN mutations
por: Truszkowska, Grażyna T, et al.
Publicado: (2015)

Analysis of De Novo Mutations in Sporadic Cardiomyopathies Emphasizes Their Clinical Relevance and Points to Novel Candidate Genes
por: Franaszczyk, Maria, et al.
Publicado: (2020)

Rapid and effective response of the R222Q SCN5A to quinidine treatment in a patient with Purkinje-related ventricular arrhythmia and familial dilated cardiomyopathy: a case report
por: Zakrzewska-Koperska, Joanna, et al.
Publicado: (2018)

Homozygous truncating mutation in NRAP gene identified by whole exome sequencing in a patient with dilated cardiomyopathy
por: Truszkowska, Grażyna T., et al.
Publicado: (2017)

LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies
por: Saj, Michal, et al.
Publicado: (2013)

Good performance of the criteria of American College of Medical Genetics and Genomics/Association for Molecular Pathology in prediction of pathogenicity of genetic variants causing thoracic aortic aneurysms and dissections
por: Ponińska, Joanna Kinga, et al.
Publicado: (2022)

Can Circulating Cardiac Biomarkers Be Helpful in the Assessment of LMNA Mutation Carriers?
por: Chmielewski, Przemyslaw, et al.
Publicado: (2020)

A combination of quinidine/mexiletine reduces arrhythmia in dilated cardiomyopathy in two patients with R814W SCN5A mutation
por: Zakrzewska‐Koperska, Joanna, et al.
Publicado: (2020)

A different background of arrhythmia in siblings with a positive family history of sudden death at young age
por: Stępień‐Wojno, Małgorzata, et al.
Publicado: (2019)

Variable clinical presentation of glycogen storage disease type IV: from severe hepatosplenomegaly to cardiac insufficiency. Some discrepancies in genetic and biochemical abnormalities
por: Szymańska, Edyta, et al.
Publicado: (2017)

Hypertrophic cardiomyopathy in a 20-year-old woman
por: van Gorselen, E.O.F., et al.
Publicado: (2015)

Sudden cardiac death risk in hypertrophic cardiomyopathy: comparison between echocardiography and magnetic resonance imaging
por: Śpiewak, Mateusz, et al.
Publicado: (2021)

BAG3-related myopathy, polyneuropathy and cardiomyopathy with long QT syndrome
por: Kostera-Pruszczyk, Anna, et al.
Publicado: (2015)

Twenty-five-year-old woman with palpitations and hypertrophic cardiomyopathy
por: Akrawinthawong, Krittapoom, et al.
Publicado: (2019)

Fatal neonatal hypertrophic cardiomyopathy caused by compound heterozygous truncating MYBPC3 mutation
por: Alsters, S., et al.
Publicado: (2019)

Tripeptidyl Peptidase 1 (TPP1) Deficiency in a 36-Year-Old Patient with Cerebellar-Extrapyramidal Syndrome and Dilated Cardiomyopathy
por: Ługowska, Agnieszka, et al.
Publicado: (2021)

Impact of cardiac magnetic resonance on the diagnosis of hypertrophic cardiomyopathy - a 10-year experience with over 1000 patients
por: Śpiewak, Mateusz, et al.
Publicado: (2020)

Oxidative Stress Markers in Hypertrophic Cardiomyopathy
por: Szyguła-Jurkiewicz, Bożena, et al.
Publicado: (2021)

Description of a Cohort with a New Truncating MYBPC3 Variant for Hypertrophic Cardiomyopathy in Northern Spain
por: Fernández Suárez, Natalia, et al.
Publicado: (2023)

Pathogenic variants in plakophilin-2 gene (PKP2) are associated with better survival in arrhythmogenic right ventricular cardiomyopathy
por: Biernacka, Elżbieta K., et al.
Publicado: (2021)

Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy
por: Lopes, Luis R, et al.
Publicado: (2021)

Hypertrophic cardiomyopathy
por: Antunes, Murillo de Oliveira, et al.
Publicado: (2020)

Hypertrophic Cardiomyopathy
por: Butt, Asra K., et al.
Publicado: (2023)

Multi-omics integration identifies key upstream regulators of pathomechanisms in hypertrophic cardiomyopathy due to truncating MYBPC3 mutations
por: Pei, J., et al.
Publicado: (2021)

The Feline Cardiomyopathies: 2. Hypertrophic cardiomyopathy
por: Kittleson, Mark D, et al.
Publicado: (2021)

BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants—design and status
por: Jansen, M., et al.
Publicado: (2021)

Hypertrophic Obstructive Cardiomyopathy
por: Cohen, Lawrence S.
Publicado: (1972)

The genetics of hypertrophic cardiomyopathy
por: Akhtar, Mohammed, et al.
Publicado: (2018)

Disopyramide for Hypertrophic Cardiomyopathy
por: Sanchez-Nadales, Alejandro, et al.
Publicado: (2019)

A novel LAMP2 p.G93R mutation associated with mild Danon disease presenting with familial hypertrophic cardiomyopathy
por: Xu, Jing, et al.
Publicado: (2019)

Biatrial performance in children with hypertrophic cardiomyopathy: CMR study
por: Mazurkiewicz, Łukasz, et al.
Publicado: (2018)

Overlap phenotypes of the left ventricular noncompaction and hypertrophic cardiomyopathy with complex arrhythmias and heart failure induced by the novel truncated DSC2 mutation
por: Lin, Yubi, et al.
Publicado: (2021)

ST-elevation acute coronary syndrome in a patient after heart transplant
por: Browarek, Aldona, et al.
Publicado: (2014)

Quantification of mitral regurgitation in patients with hypertrophic cardiomyopathy using aortic and pulmonary flow data: impacts of left ventricular outflow tract obstruction and different left ventricular segmentation methods
por: Śpiewak, Mateusz, et al.
Publicado: (2017)

The 4q25, 1q21, and 16q22 polymorphisms and recurrence of atrial fibrillation after pulmonary vein isolation
por: Kiliszek, Marek, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ip0nepqlmg1mivldsk5eb2frp1